The world's first malaria vaccine, which won a green light last week from European drugs regulators, will be rolled out gradually in Africa, its maker said on Wednesday.
"We believe that there should be a thoughtful, stag
GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.
GSK is forming a consumer health joint venture with Novartis, while at the same
Private equity firms are mulling over a $10 billion plan to buy and merge older drug brands of Britain's GlaxoSmithKline and France's Sanofi, the Financial Times reported on Sunday, citing sources.
U.S.-based KKR and Warbu
The US Food and Drug Administration approved GlaxoSmithKline's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.
Tanzeum will carry a warning on its label that tumors of the thy
Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as it bets on the importance of the continent in driving long-term demand for medicine.
The decision reflects the
An experimental GlaxoSmithKline drug, designed to fight heart disease in a new way, failed to meet its main goal in a major late-stage clinical study, dealing a blow to one of the company's biggest new treatment hopes.
British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.
China announced a nationwide crackdown on the sale of illegal medicine on Wednesday and said it would tighten industry regulation, piling pressure on a sector already reeling from a bribery scandal at British drugmaker GlaxoSmithKline.
Chinese police on Monday accused British drugmaker GlaxoSmithKline of channelling bribes to Chinese officials and doctors through travel agencies for six years to illegally boost sales and to raise the price of its medicines in the country.
A new once-daily Aids drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product.
Both GSK's new drug dolutegravir a